Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML.
Lo Presti V, Meringa A, Dunnebach E, van Velzen A, Moreira AV, Stam RW, Kotecha RS, Krippner-Heidenreich A, Heidenreich OT, Plantinga M, Cornel A, Sebestyen Z, Kuball J, van Til NP, Nierkens S.
Lo Presti V, et al. Among authors: plantinga m.
J Immunother Cancer. 2024 Apr 5;12(4):e008174. doi: 10.1136/jitc-2023-008174.
J Immunother Cancer. 2024.
PMID: 38580329
Free PMC article.